23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Vanda Pharmaceuticals Inc. › 2025-2026

Vanda Pharmaceuticals Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Vanda Pharmaceuticals Inc.’s Form 8-K, filed June 5, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Ballot items
  • 178Asset managers, any item
  • 1,268Fund votes
  • June 4, 2026Meeting date

Results at a glance

Meeting of June 4, 2026: 6 items on Vanda Pharmaceuticals Inc.’s Form 8-K, filed June 5, 2026: 3 elected · 3 approved.

Dissent

Notable dissent: 2 directors (14.1%, 11.8% against); 1 other board item (17.4% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Vanda Pharmaceuticals Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Vanda Pharmaceuticals Inc.

These tallies are Vanda Pharmaceuticals Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 5, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Vanda Pharmaceuticals Inc. — official shareholder meeting results, meeting held June 4, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Richard W. Dugan 33,029,0495,417,32246,718 --10,016,817 86%Elected—
Elect Director: Charles C. Duncan, Ph.D. 35,780,0312,664,88948,169 --10,016,817 93%Elected—
Elect Director: Anne Sempowski Ward 33,897,7824,543,48851,819 --10,016,817 88%Elected—
2. Ratification of Selection of PricewaterhouseCoopers LLP 48,103,698340,51365,695 ---- 99.3%Approved—
3. Advisory Vote on Named Executive Officer Compensation 35,242,6593,167,24383,187 --10,016,817 92%Approved—
4. Amendment to the Company's 2016 Plan 31,729,9916,685,07878,020 --10,016,817 83%Approved—

Source: Vanda Pharmaceuticals Inc., Form 8-K, filed with the SEC on June 5, 2026 — read the filing on EDGAR.

How asset managers voted at the Vanda Pharmaceuticals Inc. 2025-2026 meeting

178 asset managers disclosed a vote on at least one Vanda Pharmaceuticals Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Richard W. Dugan

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%AGAINST
FOR: 33,029,049AGAINST: 5,417,322
Details: description as filed, official tally, votes by 61 asset managers

Description as filed by funds: To elect three Class II Directors: Richard W. Dugan

Vanda Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Richard W. Dugan”): 33,029,049 for, 5,417,322 against, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following directors to serve as Class II directors until the Company's 2029 annual meeting of stockholders.”
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 61 asset managers below reported 13,114,815 for, 691,699 against, 3,390 abstained.

FOR
FOR: 13,114,815AGAINST: 691,699ABSTAIN: 3,390
Largest asset managers voting on “To elect three Class II Directors: Richard W. Dugan” at Vanda Pharmaceuticals Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,528,6748,221 00For
BlackRock2,947,8110 00For
State Street1,881,1992,495 00For
Fidelity1,484,5430 00For
Charles Schwab606,2650 00For
Federated Hermes529,0830 00For
Dimensional0446,261 00Against
Nationwide238,8100 00For
Columbia Threadneedle195,0510 00For
JPMorgan185,9230 00For
American Century149,1910 00For
Northern Trust0139,780 00Against
Equitable88,64747,550 00Mixed
TIAA116,0660 00For
Goldman Sachs101,0100 00For
Invesco95,4440 00For
QUANTITATIVE MASTER SERIES LLC93,4040 00For
MFS83,7160 00For
MASTER INVESTMENT PORTFOLIO63,2920 00For
AIG/SunAmerica60,6190 00For
Brighthouse58,6190 00For
Harbor ETF Trust52,2950 00For
ProShares50,6690 00For
ALPS ETF Trust48,1160 00For
Lincoln Financial37,9818,874 00Mixed

Showing the 25 largest of 61 asset managers. All 61 are in the interactive database (link above).

Elect Director: Charles C. Duncan, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 35,780,031AGAINST: 2,664,889
Details: description as filed, official tally, votes by 61 asset managers

Description as filed by funds: To elect three Class II Directors: Charles C. Duncan, Ph.D.

Vanda Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Charles C. Duncan, Ph.D.”): 35,780,031 for, 2,664,889 against, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following directors to serve as Class II directors until the Company's 2029 annual meeting of stockholders.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 61 asset managers below reported 13,805,983 for, 531 against, 3,390 abstained.

FOR
FOR: 13,805,983AGAINST: 531ABSTAIN: 3,390
Largest asset managers voting on “To elect three Class II Directors: Charles C. Duncan, Ph.D.” at Vanda Pharmaceuticals Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,536,88510 00For
BlackRock2,947,8110 00For
State Street1,883,173521 00For
Fidelity1,484,5430 00For
Charles Schwab606,2650 00For
Federated Hermes529,0830 00For
Dimensional446,2610 00For
Nationwide238,8100 00For
Columbia Threadneedle195,0510 00For
JPMorgan185,9230 00For
American Century149,1910 00For
Northern Trust139,7800 00For
Equitable136,1970 00For
TIAA116,0660 00For
Goldman Sachs101,0100 00For
Invesco95,4440 00For
QUANTITATIVE MASTER SERIES LLC93,4040 00For
MFS83,7160 00For
MASTER INVESTMENT PORTFOLIO63,2920 00For
AIG/SunAmerica60,6190 00For
Brighthouse58,6190 00For
Harbor ETF Trust52,2950 00For
ProShares50,6690 00For
ALPS ETF Trust48,1160 00For
Lincoln Financial46,8550 00For

Showing the 25 largest of 61 asset managers. All 61 are in the interactive database (link above).

Elect Director: Anne Sempowski Ward

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%
FOR: 33,897,782AGAINST: 4,543,488
Details: description as filed, official tally, votes by 61 asset managers

Description as filed by funds: To elect three Class II Directors: Anne Sempowski Ward

Vanda Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Anne Sempowski Ward”): 33,897,782 for, 4,543,488 against, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following directors to serve as Class II directors until the Company's 2029 annual meeting of stockholders.”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 61 asset managers below reported 13,257,355 for, 549,159 against, 3,390 abstained.

FOR
FOR: 13,257,355AGAINST: 549,159ABSTAIN: 3,390
Largest asset managers voting on “To elect three Class II Directors: Anne Sempowski Ward” at Vanda Pharmaceuticals Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,531,3595,536 00For
BlackRock2,947,8110 00For
State Street1,881,2732,421 00For
Fidelity1,484,5430 00For
Charles Schwab606,2650 00For
Federated Hermes529,0830 00For
Dimensional0446,261 00Against
Nationwide238,8100 00For
Columbia Threadneedle195,0510 00For
JPMorgan185,9230 00For
American Century149,1910 00For
Northern Trust139,7800 00For
Equitable88,64747,550 00Mixed
TIAA116,0660 00For
Goldman Sachs101,0100 00For
Invesco95,4440 00For
QUANTITATIVE MASTER SERIES LLC93,4040 00For
MFS83,7160 00For
MASTER INVESTMENT PORTFOLIO63,2920 00For
AIG/SunAmerica60,6190 00For
Brighthouse58,6190 00For
Harbor ETF Trust52,2950 00For
ProShares50,6690 00For
ALPS ETF Trust48,1160 00For
Lincoln Financial37,9818,874 00Mixed

Showing the 25 largest of 61 asset managers. All 61 are in the interactive database (link above).

Amendment to the Company's 2016 Plan

Official resultCOMPENSATIONReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

83% Approved · of votes cast

FOR 83%AGAINST
FOR: 31,729,991AGAINST: 6,685,078
Details: description as filed, official tally, votes by 61 asset managers

Description as filed by funds: TO APPROVE AN AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED 2016 EQUITY INCENTIVE PLAN, AS AMENDED TO INCREASE THE AGGREGATE NUMBER OF SHARES AUTHORIZED FOR ISSUANCE THEREUNDER.

Vanda Pharmaceuticals Inc.’s own tally for this item (“4. Amendment to the Company's 2016 Plan”): 31,729,991 for, 6,685,078 against — passed, per its Form 8-K filed June 5, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved an amendment to the 2016 Plan to increase the aggregate number of shares authorized for issuance under the 2016 Plan.”
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 61 asset managers below reported 11,201,691 for, 2,604,822 against, 3,390 abstained.

FORAGAINST
FOR: 11,201,691AGAINST: 2,604,822ABSTAIN: 3,390
Largest asset managers voting on “TO APPROVE AN AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED 2016 EQUITY INCENTIVE PLAN, AS AMENDED TO INCREA” at Vanda Pharmaceuticals Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,531,3505,544 00For
BlackRock2,947,8110 00For
State Street3,5011,880,193 00Against
Fidelity1,484,5430 00For
Charles Schwab606,2650 00For
Federated Hermes0529,083 00Against
Dimensional446,2610 00For
Nationwide238,8100 00For
Columbia Threadneedle195,0510 00For
JPMorgan185,9230 00For
American Century0149,191 00Against
Northern Trust139,7800 00For
Equitable136,1970 00For
TIAA116,0660 00For
Goldman Sachs101,0100 00For
Invesco95,4440 00For
QUANTITATIVE MASTER SERIES LLC93,4040 00For
MFS83,7160 00For
MASTER INVESTMENT PORTFOLIO63,2920 00For
AIG/SunAmerica60,6190 00For
Brighthouse58,6190 00For
Harbor ETF Trust52,2950 00For
ProShares50,6690 00For
ALPS ETF Trust48,1160 00For
Lincoln Financial8,87437,981 00Mixed

Showing the 25 largest of 61 asset managers. All 61 are in the interactive database (link above).

Advisory Vote on Named Executive Officer Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

92% Approved · of votes cast

FOR 92%
FOR: 35,242,659AGAINST: 3,167,243

Prior year: 73.9% for (June 5, 2025 meeting) ▲ 17.8 pts

Details: description as filed, official tally, votes by 178 asset managers

Description as filed by funds: To approve, on an advisory basis, the Company's named executive officer compensation.

Vanda Pharmaceuticals Inc.’s own tally for this item (“3. Advisory Vote on Named Executive Officer Compensation”): 35,242,659 for, 3,167,243 against — passed, per its Form 8-K filed June 5, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved on an advisory, non-binding basis the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 61 asset managers voting on “To approve, on an advisory basis, the Company's named executive officer compensation.” at Vanda Pharmaceuticals Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,536,88312 00For
BlackRock2,947,8110 00For
State Street1,883,62074 00For
Fidelity1,484,5430 00For
Charles Schwab606,2650 00For
Federated Hermes529,0830 00For
Dimensional446,2610 00For
Nationwide238,8100 00For
Columbia Threadneedle195,0510 00For
JPMorgan185,9230 00For
American Century0149,191 00Against
Northern Trust139,7800 00For
Equitable136,1970 00For
TIAA116,0660 00For
Goldman Sachs101,0100 00For
Invesco95,4440 00For
QUANTITATIVE MASTER SERIES LLC93,4040 00For
MFS83,7160 00For
MASTER INVESTMENT PORTFOLIO63,2920 00For
AIG/SunAmerica60,6190 00For
Brighthouse58,6190 00For
Harbor ETF Trust52,2950 00For
ProShares50,6690 00For
ALPS ETF Trust48,1160 00For
Lincoln Financial46,8550 00For

Fund voting reports, all 61 managers: 13,652,956 for, 153,558 against, 3,390 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 134 asset managers voting on “To approve, on an advisory basis, the Company's named executive officer compensation.” at Vanda Pharmaceuticals Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock3,237,1070 00For
State Street3,012,5904,437 00For
Renaissance2,497,1220 00For
AIGH Capital Management LLC1,861,1770 00For
GEODE CAPITAL MANAGEMENT, LLC1,456,8630 00For
AQR1,423,7860 00For
ACADIAN ASSET MANAGEMENT LLC1,315,4350 00For
JACOBS LEVY EQUITY MANAGEMENT, INC689,4270 00For
Charles Schwab606,3710 00For
Federated Hermes552,9727,779 00For
Vanguard461,7680 00For
Two Sigma430,1020 00For
Northern Trust398,7132,901 00For
MARSHALL WACE, LLP385,5560 00For
Citadel339,6850 00For
Monaco Asset Management SAM0241,286 00Against
Dimensional231,2620 00For
KENNEDY CAPITAL MANAGEMENT LLC216,6930 00For
Janney Montgomery Scott LLC175,0040 00For
MELLON INVESTMENTS Corp0167,892 00Against
Goldman Sachs160,1360 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC150,8390 00For
American Century0149,319 00Against
Invesco143,4450 00For
Allianz0126,681 00Against

Institutional-manager reports, all 134 managers: 21,607,976 for, 730,828 against. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Selection of PricewaterhouseCoopers LLP

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.3% Approved · of votes cast

FOR 99.3%
FOR: 48,103,698AGAINST: 340,513
Details: description as filed, official tally, votes by 61 asset managers

Description as filed by funds: To ratify the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2026.

Vanda Pharmaceuticals Inc.’s own tally for this item (“2. Ratification of Selection of PricewaterhouseCoopers LLP”): 48,103,698 for, 340,513 against — passed, per its Form 8-K filed June 5, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection, by the Audit Committee of the Board, of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 61 asset managers below reported 13,803,457 for, 3,057 against, 3,390 abstained.

FOR
FOR: 13,803,457AGAINST: 3,057ABSTAIN: 3,390
Largest asset managers voting on “To ratify the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers” at Vanda Pharmaceuticals Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,534,2102,685 00For
BlackRock2,947,8110 00For
State Street1,883,62074 00For
Fidelity1,484,5430 00For
Charles Schwab606,2650 00For
Federated Hermes529,0830 00For
Dimensional446,2610 00For
Nationwide238,8100 00For
Columbia Threadneedle195,0510 00For
JPMorgan185,9230 00For
American Century149,1910 00For
Northern Trust139,7800 00For
Equitable136,1970 00For
TIAA116,0660 00For
Goldman Sachs101,0100 00For
Invesco95,4440 00For
QUANTITATIVE MASTER SERIES LLC93,4040 00For
MFS83,7160 00For
MASTER INVESTMENT PORTFOLIO63,2920 00For
AIG/SunAmerica60,6190 00For
Brighthouse58,6190 00For
Harbor ETF Trust52,2950 00For
ProShares50,6690 00For
ALPS ETF Trust48,1160 00For
Lincoln Financial46,8550 00For

Showing the 25 largest of 61 asset managers. All 61 are in the interactive database (link above).

Largest Vanda Pharmaceuticals Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 60,135,062 shares outstanding at the time of that meeting.

Fund voting reports: top Vanda Pharmaceuticals Inc. shareholders by shares voted on “To approve, on an advisory basis, the Company's named executive officer compensation.”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 5.88%
2BlackRock 4.90%
3State Street 3.13%
4Fidelity 2.47%
5Charles Schwab 1.01%
6Federated Hermes 0.88%
7Dimensional 0.74%
8Nationwide 0.40%
9Columbia Threadneedle 0.32%
10JPMorgan 0.31%
Institutional-manager reports: top Vanda Pharmaceuticals Inc. shareholders by shares voted on “To approve, on an advisory basis, the Company's named executive officer compensation.”, 2025-2026
#Asset manager % of shares outstanding
1BlackRock 5.38%
2State Street 5.02%
3Renaissance 4.15%
4AIGH Capital Management LLC 3.09%
5GEODE CAPITAL MANAGEMENT, LLC 2.42%
6AQR 2.37%
7ACADIAN ASSET MANAGEMENT LLC 2.19%
8JACOBS LEVY EQUITY MANAGEMENT, INC 1.15%
9Charles Schwab 1.01%
10Federated Hermes 0.93%

Reported Vanda Pharmaceuticals Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Vanda Pharmaceuticals Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock, Inc.4,699,280 7.81%Proxy statement (DEF 14A), proxy filed April 23, 2026
Vanguard Group3,731,851 6.21%Form 13F, quarter ended March 31, 2026
Renaissance Technologies LLC3,681,125 6.12%Proxy statement (DEF 14A), proxy filed April 23, 2026
Millennium Management LLC3,376,401 5.61%Schedule 13G, filed August 19, 2026
Mihael H. Polymeropoulos, M.D.3,062,410 5.09%Proxy statement (DEF 14A), proxy filed April 23, 2026
State Street3,015,562 5.01%Form 13F, quarter ended March 31, 2026
BlackRock Portfolio Management LLC2,508,488 4.17%Schedule 13G, filed April 29, 2026
Dimensional Fund Advisors1,771,593 2.95%Form 13F, quarter ended March 31, 2026
Geode Capital1,442,965 2.40%Form 13F, quarter ended March 31, 2026
Two Sigma1,398,201 2.33%Form 13F, quarter ended March 31, 2026

Percentages above are of 60,135,062 shares outstanding, as reported by Vanda Pharmaceuticals Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Vanda Pharmaceuticals Inc.'s shareholder meeting held June 4, 2026, in the 2025-2026 proxy season, 178 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 1,268 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the Company's named executive officer compensation. — Vanda Pharmaceuticals Inc.'s filing reports the proposal as approved, with 92% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Vanda Pharmaceuticals Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 5, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Vanda Pharmaceuticals Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Vanda Pharmaceuticals Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Vanda Pharmaceuticals (VNDA) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/vanda-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.